Investing News NetworkDecember 11, 2024Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the 'Company', 'Sona') announces results from its most recent preclinical study of its Targeted Hyperthermia Therapy ('THT') which uses the Company's patented, biocompatible gold nanorods ('GNRs') to treat certain solid cancer tumors, shrinking them and acting as an immune stimulator.

投资新闻网2024年12月11日，SONA Nanotech Inc.（CSE:SONA）（OTCQB:SNANF）（“公司”，“SONA”）宣布了其最近针对其靶向热疗（“THT”）的临床前研究结果，该研究使用该公司获得专利的生物相容性金纳米棒（“GNR”）治疗某些实体癌肿瘤，缩小它们并充当免疫刺激剂。

Building on its success in melanoma and breast cancer studies, the Company's third preclinical efficacy study was conducted in an immunologically 'cold' colorectal cancer model ('CT26'), a model that represents the majority of human colon cancers, which do not typically respond to current standard of care immunotherapies.In this preliminary study, whereas no mice that were given standard immunotherapy alone showed any response, 100% of mice in the THT treatment group responded to the same immunotherapy with 50% (4 out of 8) of those tumors eliminated within 12 days of treatment, as shown by the green line in Figure 1, below.

在黑色素瘤和乳腺癌研究取得成功的基础上，该公司的第三项临床前疗效研究是在免疫学“冷”结直肠癌模型（“CT26”）中进行的，该模型代表了大多数人类结肠癌，通常对目前的护理标准免疫疗法没有反应。在这项初步研究中，虽然没有单独给予标准免疫疗法的小鼠显示出任何反应，但THT治疗组中100%的小鼠对相同的免疫疗法有反应，其中50%（8个中的4个）的肿瘤在治疗后12天内被消除，如下图1中的绿线所示。

Sona Nanotech CEO, David Regan, commented, 'The further preclinical evidence presented in compelling data gives us greater confidence as to Sona's THT's ability to prime non-responding tumors, thereby enhancing immunotherapy's ability to respond. As we move closer towards securing early feasibility studies to gain human data, we look forward to sharing concrete examples of THT's ability to lift the response rate of immunotherapies for patients suffering from cancer.'Preliminary detailed cellular analysis of THT-treated tumors revealed increased immune cell infiltration into the tumor microenvironment with elevated expression of PD-1 receptors on both CD4+ T-helper cells and CD8+ cytotoxic T cells.

Sona Nanotech首席执行官David Regan评论道：“令人信服的数据中提供的进一步临床前证据使我们对Sona的THT引发无反应肿瘤的能力更有信心，从而增强了免疫疗法的反应能力。随着我们更接近于确保早期可行性研究以获得人类数据，我们期待着分享THT能够提高癌症患者免疫治疗反应率的具体例子。”THT处理的肿瘤的初步详细细胞分析显示免疫细胞浸润到肿瘤微环境中，CD4+T辅助细胞和CD8+细胞毒性T细胞上PD-1受体的表达升高。

The elevated expression of PD-1 and heightened immune cell activation further supports t.

PD-1表达升高和免疫细胞活化增强进一步支持t。